SK86994A3 - Amadori reactions compounds and products, process for their manufacture, and their use - Google Patents
Amadori reactions compounds and products, process for their manufacture, and their use Download PDFInfo
- Publication number
- SK86994A3 SK86994A3 SK869-94A SK86994A SK86994A3 SK 86994 A3 SK86994 A3 SK 86994A3 SK 86994 A SK86994 A SK 86994A SK 86994 A3 SK86994 A3 SK 86994A3
- Authority
- SK
- Slovakia
- Prior art keywords
- reaction
- group
- amino acid
- mixture
- daltons
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 238000003691 Amadori rearrangement reaction Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 18
- 230000008569 process Effects 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title description 7
- 229940024606 amino acid Drugs 0.000 claims abstract description 30
- 235000001014 amino acid Nutrition 0.000 claims abstract description 30
- 150000001413 amino acids Chemical class 0.000 claims abstract description 26
- 150000004676 glycans Chemical class 0.000 claims abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 15
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 15
- 239000005017 polysaccharide Substances 0.000 claims abstract description 15
- 239000008103 glucose Substances 0.000 claims abstract description 13
- -1 treonine Chemical compound 0.000 claims abstract description 12
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 11
- 229930182830 galactose Natural products 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Chemical class 0.000 claims abstract description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 7
- 229960001153 serine Drugs 0.000 claims abstract description 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 6
- 229960003136 leucine Drugs 0.000 claims abstract description 6
- 229960002429 proline Drugs 0.000 claims abstract description 6
- 229960004441 tyrosine Drugs 0.000 claims abstract description 6
- 208000007976 Ketosis Diseases 0.000 claims abstract description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 5
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004472 Lysine Substances 0.000 claims abstract description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960002433 cysteine Drugs 0.000 claims abstract description 5
- 235000018417 cysteine Nutrition 0.000 claims abstract description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960000310 isoleucine Drugs 0.000 claims abstract description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960003646 lysine Drugs 0.000 claims abstract description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960004295 valine Drugs 0.000 claims abstract description 5
- 239000004474 valine Substances 0.000 claims abstract description 5
- 239000004475 Arginine Substances 0.000 claims abstract description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 4
- 229930091371 Fructose Natural products 0.000 claims abstract description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 4
- 239000005715 Fructose Substances 0.000 claims abstract description 4
- 239000004471 Glycine Substances 0.000 claims abstract description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000009697 arginine Nutrition 0.000 claims abstract description 4
- 229960003121 arginine Drugs 0.000 claims abstract description 4
- 229960001230 asparagine Drugs 0.000 claims abstract description 4
- 235000009582 asparagine Nutrition 0.000 claims abstract description 4
- 229960003067 cystine Drugs 0.000 claims abstract description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000004554 glutamine Nutrition 0.000 claims abstract description 4
- 229960002743 glutamine Drugs 0.000 claims abstract description 4
- 229960002591 hydroxyproline Drugs 0.000 claims abstract description 4
- 229930182817 methionine Natural products 0.000 claims abstract description 4
- 229960004452 methionine Drugs 0.000 claims abstract description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960005190 phenylalanine Drugs 0.000 claims abstract description 4
- 235000008729 phenylalanine Nutrition 0.000 claims abstract description 4
- 235000013930 proline Nutrition 0.000 claims abstract description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims abstract description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004799 tryptophan Drugs 0.000 claims abstract description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 3
- 239000004220 glutamic acid Substances 0.000 claims abstract description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract 6
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims abstract 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract 3
- 229960002442 glucosamine Drugs 0.000 claims abstract 3
- 235000000346 sugar Nutrition 0.000 claims abstract 2
- 239000007795 chemical reaction product Substances 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 14
- 150000002772 monosaccharides Chemical class 0.000 claims description 13
- 235000014633 carbohydrates Nutrition 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000011541 reaction mixture Substances 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 7
- 239000003415 peat Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- 235000008521 threonine Nutrition 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 2
- 239000000337 buffer salt Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004140 ketosis Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 abstract description 20
- 102000004127 Cytokines Human genes 0.000 abstract description 14
- 108090000695 Cytokines Proteins 0.000 abstract description 14
- 108010050904 Interferons Proteins 0.000 abstract description 8
- 102000014150 Interferons Human genes 0.000 abstract description 8
- 229940079322 interferon Drugs 0.000 abstract description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 abstract description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 5
- 150000002482 oligosaccharides Polymers 0.000 abstract description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract description 4
- 229960003767 alanine Drugs 0.000 abstract description 4
- 229960005261 aspartic acid Drugs 0.000 abstract description 4
- 229960002885 histidine Drugs 0.000 abstract description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 3
- 235000004279 alanine Nutrition 0.000 abstract description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract description 3
- 235000003704 aspartic acid Nutrition 0.000 abstract description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 abstract description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract description 3
- 235000014304 histidine Nutrition 0.000 abstract description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 3
- SHZGCJCMOBCMKK-QYESYBIKSA-N 6-deoxyglucose Chemical compound C[C@@H]1O[C@H](O)[C@@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-QYESYBIKSA-N 0.000 abstract 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 239000006035 Tryptophane Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 235000021309 simple sugar Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 18
- 230000004071 biological effect Effects 0.000 description 16
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 210000004988 splenocyte Anatomy 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000004166 bioassay Methods 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000000686 immunotropic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000276 potassium ferrocyanide Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000221012 Viscum Species 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N alpha-D-rhamnose Chemical compound C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 230000000263 nonmitogenic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 231100000628 reference dose Toxicity 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL29346492A PL171023B1 (pl) | 1992-02-13 | 1992-02-13 | Sposób wytwarzania nowych induktorów cytokin |
| EP92103614 | 1992-03-03 | ||
| PCT/EP1993/000327 WO1993016087A2 (en) | 1992-02-13 | 1993-02-11 | Amadori reaction compounds and products, process for their manufacture, and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK86994A3 true SK86994A3 (en) | 1995-02-08 |
Family
ID=26130822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK869-94A SK86994A3 (en) | 1992-02-13 | 1993-02-11 | Amadori reactions compounds and products, process for their manufacture, and their use |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5723504A (bg) |
| JP (1) | JPH07506344A (bg) |
| AT (1) | ATE187734T1 (bg) |
| AU (1) | AU672595B2 (bg) |
| BG (1) | BG62172B1 (bg) |
| BR (1) | BR9305878A (bg) |
| CA (1) | CA2130106A1 (bg) |
| CZ (1) | CZ285200B6 (bg) |
| DE (2) | DE632813T1 (bg) |
| ES (1) | ES2072244T1 (bg) |
| FI (1) | FI943733A (bg) |
| GR (1) | GR950300017T1 (bg) |
| HU (1) | HUT70434A (bg) |
| MX (1) | MX9300759A (bg) |
| NO (1) | NO304026B1 (bg) |
| RO (1) | RO115633B1 (bg) |
| RU (1) | RU2141337C1 (bg) |
| SG (1) | SG52390A1 (bg) |
| SK (1) | SK86994A3 (bg) |
| TW (1) | TW302368B (bg) |
| WO (1) | WO1993016087A2 (bg) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629412A (en) * | 1994-07-11 | 1997-05-13 | Glinskii; Guennadi V. | Synthetic glycoamines that promote or inhibit cell adhesion |
| FR2746316B1 (fr) * | 1996-03-19 | 1998-06-12 | Guerlain | Nouvelles compositions cosmetologiques ou dermatologiques |
| WO1997049389A1 (en) * | 1996-06-27 | 1997-12-31 | The Picower Institute For Medical Research | 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor |
| DE19705233A1 (de) * | 1997-02-12 | 1998-08-13 | Froelich Juergen C | Verfahren zur Herstellung einer Formulierung enthaltend Arginin |
| GB0319463D0 (en) * | 2003-08-20 | 2003-09-17 | Givaudan Sa | Compounds |
| TW200925268A (en) * | 2007-12-06 | 2009-06-16 | Mallinckrodt Baker Inc | Fluoride-containing photoresist stripper or residue removing cleaning compositions containing conjugate oligomeric or polymeric material of alpha-hydroxycarbonyl compound/amine or ammonia reaction |
| JP2012140360A (ja) * | 2010-12-28 | 2012-07-26 | Kracie Home Products Ltd | 抗酸化剤、化粧料、飲食品組成物及び医薬品組成物 |
| JP5835894B2 (ja) * | 2010-12-29 | 2015-12-24 | クラシエホームプロダクツ株式会社 | チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白剤、並びにこれらを含有する化粧料、飲食品組成物及び医薬品組成物 |
| JP2012140378A (ja) * | 2010-12-29 | 2012-07-26 | Kracie Home Products Ltd | チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白剤、並びにこれらを含有する化粧料、飲食品組成物及び医薬品組成物 |
| JP2012140377A (ja) * | 2010-12-29 | 2012-07-26 | Kracie Home Products Ltd | チロシナーゼ活性阻害剤、メラニン産生抑制剤及び美白剤、並びにこれらを含有する化粧料、飲食品組成物及び医薬品組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1514910A (en) * | 1974-07-02 | 1978-06-21 | Unilever Ltd | Amadori compounds and their use to flavour foods |
| US4629692A (en) * | 1982-12-06 | 1986-12-16 | Miles Laboratories, Inc. | Immunoassay for nonenzymatically glucosylated proteins and protein fragments an index of glycemia |
| DE3405841A1 (de) * | 1984-02-17 | 1985-08-22 | Bayer Ag, 5090 Leverkusen | N-acylierte 1-alkylamino-1-desoxy-ketose-derivate, verfahren zur herstellung und ihre verwendung |
| DE3601472A1 (de) * | 1986-01-20 | 1987-07-23 | Fresenius Ag | Verwendung von umsetzungsprodukten von reduzierenden zuckern und serotonin oder serotonin-precursoren zur behandlung cerebraler stoerungen |
| DK163689A (da) * | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
| WO1992016216A1 (en) * | 1991-03-16 | 1992-10-01 | Torf Establishment | Peat-derived bioactive products and pharmaceutical and cosmetic compositions containing them |
-
1993
- 1993-02-11 RU RU94040167A patent/RU2141337C1/ru active
- 1993-02-11 ES ES93903950T patent/ES2072244T1/es active Pending
- 1993-02-11 SG SG1996003877A patent/SG52390A1/en unknown
- 1993-02-11 BR BR9305878A patent/BR9305878A/pt not_active Application Discontinuation
- 1993-02-11 RO RO94-01361A patent/RO115633B1/ro unknown
- 1993-02-11 DE DE0632813T patent/DE632813T1/de active Pending
- 1993-02-11 HU HU9402347A patent/HUT70434A/hu unknown
- 1993-02-11 DE DE69327310T patent/DE69327310D1/de not_active Expired - Lifetime
- 1993-02-11 CA CA002130106A patent/CA2130106A1/en not_active Abandoned
- 1993-02-11 CZ CZ941945A patent/CZ285200B6/cs not_active IP Right Cessation
- 1993-02-11 JP JP5513786A patent/JPH07506344A/ja not_active Ceased
- 1993-02-11 AT AT93903950T patent/ATE187734T1/de not_active IP Right Cessation
- 1993-02-11 AU AU34966/93A patent/AU672595B2/en not_active Ceased
- 1993-02-11 SK SK869-94A patent/SK86994A3/sk unknown
- 1993-02-11 WO PCT/EP1993/000327 patent/WO1993016087A2/en active IP Right Grant
- 1993-02-11 US US08/284,635 patent/US5723504A/en not_active Expired - Fee Related
- 1993-02-12 MX MX9300759A patent/MX9300759A/es unknown
- 1993-03-23 TW TW082102133A patent/TW302368B/zh active
-
1994
- 1994-08-05 BG BG98956A patent/BG62172B1/bg unknown
- 1994-08-08 NO NO942930A patent/NO304026B1/no unknown
- 1994-08-12 FI FI943733A patent/FI943733A/fi unknown
-
1995
- 1995-04-30 GR GR950300017T patent/GR950300017T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUT70434A (en) | 1995-10-30 |
| ES2072244T1 (es) | 1995-07-16 |
| DE69327310D1 (de) | 2000-01-20 |
| FI943733A0 (fi) | 1994-08-12 |
| NO942930D0 (no) | 1994-08-08 |
| RU2141337C1 (ru) | 1999-11-20 |
| GR950300017T1 (en) | 1995-04-30 |
| WO1993016087A2 (en) | 1993-08-19 |
| NO304026B1 (no) | 1998-10-12 |
| RU94040167A (ru) | 1996-07-10 |
| ATE187734T1 (de) | 2000-01-15 |
| CA2130106A1 (en) | 1993-08-14 |
| MX9300759A (es) | 1993-11-01 |
| US5723504A (en) | 1998-03-03 |
| DE632813T1 (de) | 1996-02-15 |
| HU9402347D0 (en) | 1994-10-28 |
| AU672595B2 (en) | 1996-10-10 |
| FI943733A (fi) | 1994-08-12 |
| RO115633B1 (ro) | 2000-04-28 |
| CZ194594A3 (en) | 1994-12-15 |
| CZ285200B6 (cs) | 1999-06-16 |
| BG62172B1 (bg) | 1999-04-30 |
| BG98956A (bg) | 1995-07-28 |
| WO1993016087A3 (en) | 1993-09-16 |
| AU3496693A (en) | 1993-09-03 |
| SG52390A1 (en) | 1998-09-28 |
| TW302368B (bg) | 1997-04-11 |
| BR9305878A (pt) | 1997-08-19 |
| JPH07506344A (ja) | 1995-07-13 |
| NO942930L (no) | 1994-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5736519A (en) | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide | |
| SK86994A3 (en) | Amadori reactions compounds and products, process for their manufacture, and their use | |
| EP0818462B1 (en) | Glu-trp comprising tripeptides | |
| JPH07505371A (ja) | 免疫調節活性を有する新規親油性オリゴペプチド | |
| EP0316408A1 (en) | Method of tumor inhibition in warm-blooded animals | |
| EP3392263A1 (en) | Polypeptide compound, preparation method therefor and use thereof | |
| PL171319B1 (pl) | S posób wytwarzania kompozycji przydatnej do uzytku farmaceutycznegoi/lub kosmetycznego PL PL PL | |
| Thierry et al. | Synthesis and activity of NAcSerAspLysPro analogs on cellular interactions between T-cell and erythrocytes in rosette formation | |
| US4399124A (en) | Peptides having immunostimulating properties and pharmaceutical compositions containing them | |
| AU665789B2 (en) | Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof | |
| EP0632813B1 (en) | Amadori reaction compounds and products, process for their manufacture, and their use | |
| JPS5959654A (ja) | ホルモン放出因子類似体及びその製造方法 | |
| HU208160B (en) | Process for producing t-butyl-oxycarbonyl-1-tyrosylpeptidoglycan monomer and its derivatives marked with 125 i, as well as pharmaceutical compositions comprising same as active ingredient | |
| CA2011874C (en) | Sdk peptides, a preparation process of the same and therapeutic compositions containing them | |
| US6458761B2 (en) | Synthetic, statistic thymic peptide combination and its use as a preparation with immunological and/or endocrinological effect | |
| JPH0253799A (ja) | 新規ペプチド及び抗菌剤 | |
| GR3031254T3 (en) | Novel derivatives of peptides therapeutically active in the cascade sequence for blood coagulation, process for their preparation and pharmaceutical compositions containing same | |
| GB1568195A (en) | Synthetc peptides | |
| PL171023B1 (pl) | Sposób wytwarzania nowych induktorów cytokin | |
| JPS63141996A (ja) | 新規活性ペプチド | |
| JPH07506564A (ja) | 医薬的ペンタペプチド組成物およびその使用法 | |
| JPS565801A (en) | Glycoprotein nk | |
| JPH02115198A (ja) | 動物コラゲナーゼ阻害剤 | |
| JPH06256389A (ja) | 新規なペプチドおよび免疫賦活剤 |